This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D55.2 | V code: V164 | Synonyms: Hereditary nonspherocytic hemolytic anemia, HNSHA, Enzymopathy anemia
The history of hereditary hemolytic anemia due to erythrocyte glycolytic enzyme deficiency begins with the work of Robinson and colleagues in 1954. They first reported the presence of specific biochemical abnormalities within erythrocytes in patients with hemolytic anemia, but at the time could not identify the exact enzyme abnormality. Later, in 1961, Valentine and colleagues, through systematic enzyme testing, first demonstrated that a marked reduction in pyruvate kinase (PK) activity was the cause of chronic hemolytic anemia. PK deficiency was subsequently established as the most common erythrocyte glycolytic enzyme deficiency and became the prototype for understanding the other enzyme deficiencies included under the same code (D55.2).
In the 1960s–70s, deficiencies of various erythrocyte glycolytic enzymes were reported one after another. Deficiencies of hexokinase (HK), glucose phosphate isomerase (GPI), phosphofructokinase (PFK), aldolase, triosephosphate isomerase (TPI), phosphoglycerate kinase (PGK), phosphoglycerate mutase (PGAM), enolase (ENO), pyruvate kinase (PK), lactate dehydrogenase (LDH) and others were each reported. All of these enzymes belong to glycolysis, in which glucose is broken down to lactate, and the anemias caused by their deficiency were collectively termed Hereditary Nonspherocytic Hemolytic Anemia (HNSHA). ICD-10 D55.2 was established as the code covering this entire group.
Since the 1990s, thanks to advances in molecular biology, the genes encoding each enzyme have been identified and their pathogenic variants elucidated one by one. Variant databases have been built for genes such as PKLR (PK, 1q22), HK1 (HK, 10q22.1) and GPI (GPI, 19q13.11). In particular, in 2022 the pyruvate kinase activator mitapivat (brand name Pyrukynd) received approval from the US Food and Drug Administration (FDA), opening the era of the first disease-modifying small-molecule therapy in the HNSHA field.
Mature erythrocytes lack nuclei, mitochondria and ribosomes, so protein synthesis and oxidative phosphorylation are impossible. Therefore, glycolysis is the only means of energy (ATP) supply in erythrocytes. ATP produced through glycolysis drives ion pumps such as Na+/K+-ATPase to maintain erythrocyte shape and osmotic homeostasis, maintains membrane phospholipid asymmetry, and ensures membrane deformability through interactions with cytoskeletal proteins (spectrin, ankyrin, etc.). If any one of the more than 10 enzymes involved in this process loses function, ATP depletion results, and consequently erythrocytes are prematurely destroyed in the reticuloendothelial system, such as the spleen.
Among the enzyme deficiencies corresponding to code D55.2, pyruvate kinase (PK) deficiency accounts for about 90% of the total. PK is the key enzyme that catalyzes the last ATP-generating step of glycolysis, producing pyruvate and ATP from phosphoenolpyruvate (PEP) and ADP. When PK enzyme activity is reduced due to variants in the PKLR gene encoding PK, ATP production within erythrocytes decreases and 2,3-DPG (2,3-diphosphoglycerate) accumulates. The remaining 10% includes HK, TPI, PGK, PGAM, ENO, LDH and GPI deficiencies, each of which is extremely rare.
Deficiency of each enzyme blocks ATP production at a different position within glycolysis, and each shows a unique pattern of accumulated biochemical intermediates and clinical characteristics. For example, TPI deficiency is accompanied by severe neuromuscular abnormalities in addition to HNSHA, whereas GPI deficiency mainly causes only hemolysis. Thus D55.2 is a conceptual classification encompassing various enzyme deficiencies that are clinically similar but biochemically and molecularly heterogeneous.
Most glycolytic enzyme deficiencies included in D55.2 follow an autosomal recessive mode of inheritance. As an exception, phosphoglycerate kinase (PGK) deficiency is inherited in an X-linked recessive manner. In autosomal recessive cases, heterozygous carriers mostly maintain enzyme activity at about 50% of normal and are clinically healthy, but clinical disease develops in homozygous or compound heterozygous individuals. When each parent is a carrier, the probability of disease in a child is 25%.
The gene locations of the major enzymes are summarized as follows. The PKLR gene is located on the long arm of chromosome 1 (1q22), the HK1 gene on the long arm of chromosome 10 (10q22.1), the GPI gene on chromosome 19 (19q13.11), and the TPI1 gene on chromosome 12 (12p13.31). Various missense, nonsense and splicing variants have been reported in each gene, and depending on the enzyme, common variants (founder mutations) are sometimes observed at high frequency in specific ethnic groups. For PK deficiency, hundreds of variants have been reported in the PKLR gene, including 1529A>G (p.Asp510Gly).
In patients with clinically suspected HNSHA in whom G6PD deficiency and autoimmune hemolytic anemia (AIHA) have been excluded, when measuring individual enzyme activities is difficult, a next-generation sequencing (NGS)-based erythrocyte enzymopathy panel is an efficient diagnostic strategy. In particular, because individual assays for many rare enzyme deficiencies are available only at specialized institutions, an NGS panel has the advantage of shortening the time to diagnosis and detecting multiple rare variants simultaneously.
The exact prevalence of the entire HNSHA group is difficult to determine, but for PK deficiency, the most common cause, a worldwide prevalence of about 1 per 510,000 births is estimated. In certain ethnic groups, such as the Amish community or certain East Asian regions, the prevalence may be much higher due to a founder effect. The remaining enzyme deficiencies are so rare that cumulative reported cases worldwide number only in the tens to hundreds.
In Korea, glycolytic enzyme deficiency anemia corresponding to D55.2 is extremely rare, and registered patients numbering in the tens are identified in Health Insurance Review & Assessment Service (HIRA) data and the rare disease registry database. Domestic cases of PK deficiency have been diagnosed and reported mainly through pediatrics or clinical hematology specialty institutions, while HK deficiency, TPI deficiency and the like are limited to isolated case reports.
Except for PGK deficiency, most glycolytic enzyme deficiencies occur with equal frequency in males and females. Severe homozygous patients present around birth with neonatal jaundice or fetal hydrops, while mild compound heterozygotes are sometimes diagnosed when they first experience a hemolytic episode under infectious stress in childhood or adulthood. In particular, in heterozygous carriers, a transient worsening of hemolysis in stressful situations such as pregnancy, infection or surgery may be the time of first presentation.
The breakdown of glucose to lactate via glycolysis consists of 10 enzymatic reaction steps. The net reaction produces a net 2 molecules of ATP per molecule of glucose and also generates NADH. Of these, the first step is the phosphorylation of glucose to glucose-6-phosphate (G6P) by hexokinase (HK), and the last ATP-generating step is the production of ATP from phosphoenolpyruvate (PEP) by pyruvate kinase (PK). Deficiency of an enzyme at any step reduces ATP production, but the pattern of accumulation of specific intermediates upstream differs depending on the enzyme's position.
When ATP is depleted, the function of Na+/K+-ATPase in the erythrocyte membrane declines, increasing Na+ influx and K+ efflux, and after osmotic swelling the membrane becomes fragile. In addition, reduced function of ATP-dependent membrane phospholipid flippase exposes phosphatidylserine (PS) on the outer cell surface, and macrophages of the spleen and liver that recognize it phagocytose the erythrocytes, causing extravascular hemolysis. In PK deficiency, accumulation of PEP and 2,3-DPG upstream is characteristic, and the increase in 2,3-DPG shifts the oxygen dissociation curve to the right, having a partial compensatory effect of improving tissue oxygen delivery.
In the bone marrow, erythropoiesis increases in response to hemolysis (reticulocytosis), but even this compensation does not fully correct the chronic anemia. Because reticulocytes still possess mitochondria and can also obtain energy through oxidative phosphorylation, they are less affected by glycolytic enzyme deficiency. However, from the moment reticulocytes lose their mitochondria as they differentiate into mature erythrocytes, they depend solely on glycolysis, and premature destruction occurs.
In severe glycolytic enzyme deficiency anemia, symptoms may appear around birth. In severe cases, hydrops fetalis may lead to stillbirth or require immediate neonatal intensive care. Neonatal jaundice is the most common initial symptom and may require exchange transfusion. Later in infancy, pallor, chronic jaundice and splenomegaly are observed, and severe anemia requiring transfusion persists.
In mild or compound heterozygous patients, symptoms may not appear through childhood to adulthood, and they are sometimes diagnosed when they first experience an episode of acute worsening of hemolysis in stressful situations such as acute infection (especially pure red cell aplasia due to parvovirus B19 infection), surgery, pregnancy or drug administration. In chronic cases, the main symptoms are fatigue, pallor, yellow sclerae, reduced exercise tolerance and abdominal pain due to gallstones (pigment stones).
Conjunctival pallor, scleral icterus and skin jaundice are typical physical findings of chronic hemolysis. Splenomegaly due to long-term hemolysis may be palpable in the left subcostal region, and in severe cases hepatomegaly also accompanies it. In patients who have received transfusions over a long period, signs such as skin pigmentation, diabetes and endocrine dysfunction due to iron overload may appear. In TPI deficiency, neurological signs (hypotonia, developmental delay, movement abnormalities) are observed as well.
The complete blood count shows normocytic or macrocytic anemia and a marked increase in reticulocytes (several to tens of times normal). Elevated serum indirect bilirubin, elevated LDH and decreased haptoglobin are markers of hemolysis. In PK deficiency in particular, crenated erythrocytes (echinocytes, burr cells) are prominently observed on peripheral blood smear after splenectomy. APTT (activated partial thromboplastin time) and PT (prothrombin time) are within the normal range, and the direct antiglobulin test (DAT) is negative.
A fluorescent spot test is performed as initial screening to exclude G6PD deficiency. When G6PD is normal while hemolytic anemia persists, there is no spherocytosis and the DAT is negative, the possibility of glycolytic enzyme deficiency anemia (D55.2) should be considered. At this point, identifying specific morphological abnormalities such as crenated erythrocytes (echinocytes) on blood smear helps narrow the diagnostic direction.
Specialized institutions perform an erythrocyte enzyme activity panel, measuring the activities of PK, HK, GPI, PFK, TPI, PGK, ENO, LDH and others all at once. The activity of each enzyme is interpreted by comparison with age- and sex-specific reference values, and when an enzyme with markedly reduced activity is identified, confirmation proceeds with molecular analysis of that enzyme's gene. If the reticulocyte count is high at the time of testing, false negatives may occur because enzyme activity is higher in young erythrocytes, so it is recommended, where possible, to separate older erythrocytes with lower activity and retest.
Quantitative spectrophotometric measurement of individual enzyme activities is the diagnostic standard. For pyruvate kinase (PK) deficiency, PK enzyme activity measurement (a coupled reaction method measuring NADH consumption, 340 nm) is used. Normal adult PK activity is about 6–20 IU/g Hb, and in patients with PK deficiency it is reduced to 5–25% of normal. Correction for reticulocyte count is important here, because the more reticulocytes there are, the higher the measured value, so the actual degree of deficiency may be underestimated.
When reduced enzyme activity is confirmed, pathogenic variants are identified by Sanger sequencing or NGS panel analysis of the relevant enzyme gene, and variant pathogenicity is classified according to ACMG/AMP criteria. In particular, because a compound heterozygous state is difficult to predict from enzyme activity measurement alone, molecular analysis is essential for clinical genetic counseling and family testing.
The differential diagnosis of HNSHA includes G6PD deficiency (D55.0), hereditary spherocytosis (D58.0), autoimmune hemolytic anemia (D59.1) and hemoglobinopathies (D56-D58). Hereditary spherocytosis is DAT negative, but spherocytes predominate and it is distinguished by a positive osmotic fragility test. Autoimmune hemolytic anemia is characterized by a positive DAT.
In severe HNSHA, red blood cell transfusion is performed when Hb is below 7 g/dL or when there is clinically anemia-related heart failure, growth failure, cognitive impairment or the like. In transfusion-dependent patients, management of iron overload is essential. Long-term folic acid intake is recommended to replace folate consumed by chronic hemolysis. Urgent transfusion is needed when pure red cell aplasia (aplastic crisis) due to parvovirus B19 infection occurs.
Splenectomy is an effective treatment for reducing transfusion frequency across the D55.2 group. In PK deficiency in particular, Hb rises by 1–3 g/dL after splenectomy and the need for transfusion decreases, but the effect is limited in some severe patients. After splenectomy, the risk of fulminant sepsis due to encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis) (OPSI, overwhelming post-splenectomy infection) increases, so vaccination and antibiotic prophylaxis are essential.
Mitapivat (Pyrukynd), approved by the FDA in 2022, is an allosteric activator of the PK enzyme and has been shown to increase erythrocyte ATP and reduce hemolysis in patients with PK deficiency. In phase 3 clinical trials (ACTIVATE and ACTIVATE-T studies), an Hb increase of 1 g/dL or more was confirmed in about 40% of non-transfusion-dependent adult patients with PK deficiency. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be considered as curative treatment in severe pediatric patients with an HLA-matched donor.
The prognosis of the enzyme deficiencies included in D55.2 varies greatly depending on the type of enzyme and the severity of the variant. With PK deficiency, many patients can enjoy a normal life expectancy if appropriately managed. In contrast, TPI deficiency is accompanied by severe neuromuscular abnormalities in addition to HNSHA, has a poor prognosis, and most patients die in childhood. GPI deficiency shows severe hemolysis in some, but often improves considerably with splenectomy.
Long-term complications of chronic hemolysis include gallstones (pigment stones, which can develop from childhood in particular), iron overload due to repeated transfusion (heart, liver, endocrine glands), infection risk after splenectomy, and extramedullary hematopoietic masses (extramedullary hematopoiesis) due to hematopoiesis outside the bone marrow, observed specifically in PK deficiency. Regular abdominal ultrasound, serum ferritin measurement, liver function tests and endocrine function assessment are necessary.
Because glycolytic enzyme deficiency anemia is mostly inherited in an autosomal recessive manner, carrier testing of parents and siblings is recommended once a patient is identified. In carrier couples, each pregnancy has a 25% chance of an affected child, and prenatal molecular diagnosis (chorionic villus sampling or amniocentesis) is technically possible. Especially in families that have previously had a severely affected infant, a plan for early intervention can be established through prenatal diagnosis.
To prevent acute worsening of hemolysis in HNSHA patients, keeping vaccinations up to date against infections (especially parvovirus B19, influenza, etc.), closer monitoring of anemia during pregnancy and optimization of hematological status before surgery are necessary. Because pure red cell aplastic crisis due to parvovirus B19 is particularly dangerous in immunocompromised patients and patients with chronic hemolytic anemia, immunoglobulin administration after exposure may be considered.